• INmune Bio entered a warrant inducement deal for April 2024 common stock purchase warrants on June 30, 2026.
• Holders agreed to cash-exercise 647,112 warrants, equal to 50% of their positions, at a reduced $1.4 strike from $1.95.
• Company expects USD 905,957 in gross proceeds from the exercises, issuing 647,112 common shares.
• Remaining 50% of the warrants had their maturity extended to Dec. 31, 2027 from June 30, 2026.
• Underlying shares are registered under an effective registration statement (File No. 333-279036).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. INmune Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-073983), on July 01, 2026, and is solely responsible for the information contained therein.